Yan-An Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan-An Wu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Biao Zhang
Department of Clinical Laboratory, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China
5 shared publicationsMingjie Li
Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, China
5 shared publicationsXiaoli Huang
Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, China
4 shared publicationsXijun Chen
Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, China
4 shared publicationsXinxin Lu
Center of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
4 shared publicationsHuiying Rao
Department of Ophthalmology, Fujian Provincial Hospital, Fuzhou, China
3 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (3) , 101371
The abnormal splicing regulation network caused by synonymous mutations in FBN1 exon 39 leads to Marfan syndrome
- 1 May 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (3) , 101371
Open AccessThe abnormal splicing regulation network caused by synonymous mutations in FBN1 exon 39 leads to Marfan syndrome
- Open Access
- 1 February 2025
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 18, 759-770
Trends and Dynamics of Respiratory Viruses in Hospitalized Children of Fuzhou: Insights Into the Impact of COVID-19 Pandemic Control Measures
Purpose: This study aimed to investigate the prevalence of common respiratory viruses among children with acute respiratory infections in Fuzhou from 2017 to 2023, considering the varying Corona Virus Disease 2019 (COVID-19) epidemic control measures in place. Patients and Methods: This study retrospectively analyzed the detection of respiratory viruses in children diagnosed with acute respiratory infections at a tertiary hospital in Fuzhou during the study period. The analysis covers three distinct phases: Phase I (2017– 2019), Phase II (2020– 2022), and Phase III (2023). The subjects of this study included adenovirus (ADV), influenza A virus (Flu A), influenza B virus (Flu B), parainfluenza virus types 1, 2, and 3 (PIV-1, PIV-2, PIV-3), and respiratory syncytial virus (RSV). Results: A total of 24,838 throat swab samples were collected, resulting in an overall positive detection rate of 17.87% (4439/24,838). The positive detection rates of respiratory viruses among hospitalized children in Phases I, II, and III were 18.51%, 18.27%, and 15.90%, respectively, demonstrating a statistically significant decreasing trend over the years (P < 0.001). Among the detected viruses, RSV, PIV-3, and Flu A were the most prevalent. RSV infections was most common in children under six years of age. Seasonal trends for Flu A, PIV-3, and RSV varied throughout the outbreak; specifically, the detection rate of Flu A increased during March and April in 2023, while RSV detection rebounded sharply from April to June. The incidence of mixed respiratory virus infections was 0.40% (100/24,838), the most common being PIV-3 and RSV. Conclusion: Using COVID-19 safety rules has helped stop the spread of some viruses in kids. But these rules have not made much difference in how often RSV and PIV-3 viruses show up.
- 1 February 2025
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 18, 759-770
Open AccessTrends and Dynamics of Respiratory Viruses in Hospitalized Children of Fuzhou: Insights Into the Impact of COVID-19 Pandemic Control Measures
Purpose: This study aimed to investigate the prevalence of common respiratory viruses among children with acute respiratory infections in Fuzhou from 2017 to 2023, considering the varying Corona Virus Disease 2019 (COVID-19) epidemic control measures in place. Patients and Methods: This study retrospectively analyzed the detection of respiratory viruses in children diagnosed with acute respiratory infections at a tertiary hospital in Fuzhou during the study period. The analysis covers three distinct phases: Phase I (2017– 2019), Phase II (2020– 2022), and Phase III (2023). The subjects of this study included adenovirus (ADV), influenza A virus (Flu A), influenza B virus (Flu B), parainfluenza virus types 1, 2, and 3 (PIV-1, PIV-2, PIV-3), and respiratory syncytial virus (RSV). Results: A total of 24,838 throat swab samples were collected, resulting in an overall positive detection rate of 17.87% (4439/24,838). The positive detection rates of respiratory viruses among hospitalized children in Phases I, II, and III were 18.51%, 18.27%, and 15.90%, respectively, demonstrating a statistically significant decreasing trend over the years (P < 0.001). Among the detected viruses, RSV, PIV-3, and Flu A were the most prevalent. RSV infections was most common in children under six years of age. Seasonal trends for Flu A, PIV-3, and RSV varied throughout the outbreak; specifically, the detection rate of Flu A increased during March and April in 2023, while RSV detection rebounded sharply from April to June. The incidence of mixed respiratory virus infections was 0.40% (100/24,838), the most common being PIV-3 and RSV. Conclusion: Using COVID-19 safety rules has helped stop the spread of some viruses in kids. But these rules have not made much difference in how often RSV and PIV-3 viruses show up.
- Open Access
- 20 January 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1507098
Clinical and genetic analysis of a Chinese family with GM1 gangliosidosis caused by a novel mutation in GLB1 gene
Objective: To describe the clinical presentation and novel mutation in the ganglioside-beta-galactosidase gene (GLB1) gene in a Chinese family with GM1 gangliosidosis.Methods: We collected clinical data from a Chinese family with GM1 gangliosidosis, and performed whole exon sequencing (WES) of the proband and his parents. The pathogenic sites of candidate genes were targeted, and the detected exon mutations were verified by Sanger sequencing. Enzyme activity of β-galactosidase was detected in 293T cells transiently transfected with plasmids encoding the detected mutations.Results: Two siblings in this family presented with neurological degeneration, and were classified as the late-infantile type. Two siblings and their parents underwent WES of the peripheral blood. A reported missense mutation c.446C>T and a novel mutation c.1058_1059delinsAA in GLB1 gene inherited from the mother and father respectively were identified. The mutant c.1058_1059delinsAA retained β-galactosidase activity at 0% of wild-type GLB1.Conclusion: This study identified a novel mutation of the GLB1 gene in a Chinese family with GM1 gangliosidosis and provided new insights into the molecular characteristics and genetic counseling of GM1 gangliosidosis.
- 20 January 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1507098
Open AccessClinical and genetic analysis of a Chinese family with GM1 gangliosidosis caused by a novel mutation in GLB1 gene
Objective: To describe the clinical presentation and novel mutation in the ganglioside-beta-galactosidase gene (GLB1) gene in a Chinese family with GM1 gangliosidosis.Methods: We collected clinical data from a Chinese family with GM1 gangliosidosis, and performed whole exon sequencing (WES) of the proband and his parents. The pathogenic sites of candidate genes were targeted, and the detected exon mutations were verified by Sanger sequencing. Enzyme activity of β-galactosidase was detected in 293T cells transiently transfected with plasmids encoding the detected mutations.Results: Two siblings in this family presented with neurological degeneration, and were classified as the late-infantile type. Two siblings and their parents underwent WES of the peripheral blood. A reported missense mutation c.446C>T and a novel mutation c.1058_1059delinsAA in GLB1 gene inherited from the mother and father respectively were identified. The mutant c.1058_1059delinsAA retained β-galactosidase activity at 0% of wild-type GLB1.Conclusion: This study identified a novel mutation of the GLB1 gene in a Chinese family with GM1 gangliosidosis and provided new insights into the molecular characteristics and genetic counseling of GM1 gangliosidosis.
- Open Access
- 5 February 2024
- Published by Springer Nature in BMC Medical Genomics
- Vol. 17 (1) , 1-10
Identification of two novel large deletions in FBN1 gene by next-generation sequencing and multiplex ligation-dependent probe amplification
Background: Mutations in fibrillin-1 (FBN1) are known to be associated with Marfan syndrome (MFS), an autosomal dominant connective tissue disorder. Most FBN1 mutations are missense or nonsense mutations. Traditional molecular genetic testing for the FBN1 gene, like Sanger sequencing, may miss disease-causing mutations in the gene’s regulatory regions or non-coding sequences, as well as partial or complete gene deletions and duplications. Methods: Next-generation sequencing, multiplex ligation-dependent probe amplification and gap PCR were conducted on two MFS patients to screen for disease-causing mutations. Results: We identified two large deletions in FBN1 from two MFS patients. One patient had a 0.23 Mb deletion (NC_000015.9:g.48550506_48779360del) including 5’UTR-exon6 of FBN1. The other patient harbored a 1416 bp deletion (NC_000015.9:g.48410869_48412284del) affecting the last exon, exon 66, of the FBN1 gene. Conclusion: Our results expanded the number of large FBN1 deletions and highlighted the importance of screening for large deletions in FBN1 in clinical genetic testing, especially for those with the classic MFS phenotype.
- 5 February 2024
- Published by Springer Nature in BMC Medical Genomics
- Vol. 17 (1) , 1-10
Open AccessIdentification of two novel large deletions in FBN1 gene by next-generation sequencing and multiplex ligation-dependent probe amplification
Background: Mutations in fibrillin-1 (FBN1) are known to be associated with Marfan syndrome (MFS), an autosomal dominant connective tissue disorder. Most FBN1 mutations are missense or nonsense mutations. Traditional molecular genetic testing for the FBN1 gene, like Sanger sequencing, may miss disease-causing mutations in the gene’s regulatory regions or non-coding sequences, as well as partial or complete gene deletions and duplications. Methods: Next-generation sequencing, multiplex ligation-dependent probe amplification and gap PCR were conducted on two MFS patients to screen for disease-causing mutations. Results: We identified two large deletions in FBN1 from two MFS patients. One patient had a 0.23 Mb deletion (NC_000015.9:g.48550506_48779360del) including 5’UTR-exon6 of FBN1. The other patient harbored a 1416 bp deletion (NC_000015.9:g.48410869_48412284del) affecting the last exon, exon 66, of the FBN1 gene. Conclusion: Our results expanded the number of large FBN1 deletions and highlighted the importance of screening for large deletions in FBN1 in clinical genetic testing, especially for those with the classic MFS phenotype.
- Open Access
- 26 June 2023
- Published by Springer Nature in Research Square
Identification of two novel large deletions in FBN1 gene by next-generation sequencing and multiplex ligation-dependent probe amplification
Background Mutations in fibrillin 1 (FBN1) are known to be associated with Marfan syndrome (MFS), an autosomal dominant connective tissue disorder. Most FBN1 mutations are missense or nonsense mutations. Conventional molecular genetic testing of FBN1 using techniques such as Sanger sequencing may miss disease-causing mutations in promoter regions or other noncoding sequences as well as partial or complete gene deletions and duplications. Methods Two MFS patients referred for genetic testing were recruited and underwent next-generation sequencing, multiplex ligation-dependent probe amplification and gap PCR to identify the causative mutation. Results We identified two large genomic deletions in FBN1 from two MFS patients. One patient had a 0.23 Mb deletion spanning FBN1 exons 1–6 and the neighboring upstream gene CEP152. The other patient harbored a 1,416 bp deletion of FBN1 exon 66. Conclusion Our report expanded the number of large FBN1 deletions and highlighted the importance of screening for large deletions in FBN1 in clinical genetic testing,especially for those with classic Marfan phenotype.
- 26 June 2023
- Published by Springer Nature in Research Square
Open AccessIdentification of two novel large deletions in FBN1 gene by next-generation sequencing and multiplex ligation-dependent probe amplification
Background Mutations in fibrillin 1 (FBN1) are known to be associated with Marfan syndrome (MFS), an autosomal dominant connective tissue disorder. Most FBN1 mutations are missense or nonsense mutations. Conventional molecular genetic testing of FBN1 using techniques such as Sanger sequencing may miss disease-causing mutations in promoter regions or other noncoding sequences as well as partial or complete gene deletions and duplications. Methods Two MFS patients referred for genetic testing were recruited and underwent next-generation sequencing, multiplex ligation-dependent probe amplification and gap PCR to identify the causative mutation. Results We identified two large genomic deletions in FBN1 from two MFS patients. One patient had a 0.23 Mb deletion spanning FBN1 exons 1–6 and the neighboring upstream gene CEP152. The other patient harbored a 1,416 bp deletion of FBN1 exon 66. Conclusion Our report expanded the number of large FBN1 deletions and highlighted the importance of screening for large deletions in FBN1 in clinical genetic testing,especially for those with classic Marfan phenotype.
- Open Access
- 16 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Transcriptome profiling and co-expression network analysis of lncRNAs and mRNAs in colorectal cancer by RNA sequencing
Long non-coding RNAs (lncRNAs) are widely involved in the pathogenesis of cancers. However, biological roles of lncRNAs in occurrence and progression of colorectal cancer (CRC) remain unclear. The current study aimed to evaluate the expression pattern of lncRNAs and messenger RNAs (mRNAs). RNA sequencing (RNA-Seq) in CRC tissues and adjacent normal tissues from 6 CRC patients was performed and functional lncRNA-mRNA co-expression network was constructed afterwards. Gene enrichment analysis was demonstrated using DAVID 6.8 tool. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to validate the expression pattern of differentially expressed lncRNAs. Pearson correlation analysis was applied to evaluate the relationships between selected lncRNAs and mRNAs. One thousand seven hundred and sixteenth differentially expressed mRNAs and 311 differentially expressed lncRNAs were screened out. Among these, 568 mRNAs were up-regulated while 1148 mRNAs down-regulated, similarly 125 lncRNAs were up-regulated and 186 lncRNAs down-regulated. In addition, 1448 lncRNA–mRNA co-expression pairs were screened out from 940,905 candidate lncRNA-mRNA pairs. Gene enrichment analysis revealed that these lncRNA-related mRNAs are associated with cell adhesion, collagen adhesion, cell differentiation, and mainly enriched in ECM-receptor interaction and PI3K-Akt signaling pathways. Finally, RT-qPCR results verified the expression pattern of lncRNAs, as well as the relationships between lncRNAs and mRNAs in 60 pairs of CRC tissues. In conclusion, these results of the RNA-seq and bioinformatic analysis strongly suggested that the dysregulation of lncRNA is involved in the complicated process of CRC development, and providing important insight regarding the lncRNAs involved in CRC.
- 16 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Open AccessTranscriptome profiling and co-expression network analysis of lncRNAs and mRNAs in colorectal cancer by RNA sequencing
Long non-coding RNAs (lncRNAs) are widely involved in the pathogenesis of cancers. However, biological roles of lncRNAs in occurrence and progression of colorectal cancer (CRC) remain unclear. The current study aimed to evaluate the expression pattern of lncRNAs and messenger RNAs (mRNAs). RNA sequencing (RNA-Seq) in CRC tissues and adjacent normal tissues from 6 CRC patients was performed and functional lncRNA-mRNA co-expression network was constructed afterwards. Gene enrichment analysis was demonstrated using DAVID 6.8 tool. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to validate the expression pattern of differentially expressed lncRNAs. Pearson correlation analysis was applied to evaluate the relationships between selected lncRNAs and mRNAs. One thousand seven hundred and sixteenth differentially expressed mRNAs and 311 differentially expressed lncRNAs were screened out. Among these, 568 mRNAs were up-regulated while 1148 mRNAs down-regulated, similarly 125 lncRNAs were up-regulated and 186 lncRNAs down-regulated. In addition, 1448 lncRNA–mRNA co-expression pairs were screened out from 940,905 candidate lncRNA-mRNA pairs. Gene enrichment analysis revealed that these lncRNA-related mRNAs are associated with cell adhesion, collagen adhesion, cell differentiation, and mainly enriched in ECM-receptor interaction and PI3K-Akt signaling pathways. Finally, RT-qPCR results verified the expression pattern of lncRNAs, as well as the relationships between lncRNAs and mRNAs in 60 pairs of CRC tissues. In conclusion, these results of the RNA-seq and bioinformatic analysis strongly suggested that the dysregulation of lncRNA is involved in the complicated process of CRC development, and providing important insight regarding the lncRNAs involved in CRC.
- Open Access
- 17 January 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9, 778859
Congenital Short-Bowel Syndrome Is Associated With a Novel Deletion Mutation in the CLMP Gene: Mutations in CLMP Caused CSBS
Objective: To describe the clinical presentation and novel mutation in the coxsackie and adenovirus receptor-like membrane protein (CLMP) gene in a Chinese family with congenital short bowel syndrome (CSBS).Methods: We collected clinical data from a Chinese family with inherited CSBS, and performed whole exon sequencing of the children and their parents. The pathogenic sites of candidate genes were targeted, and the detected exon deletions were verified by quantitative PCR.Results: Two siblings in this family presented with bilious vomiting, and were diagnosed with CSBS on laparotomy. Two siblings and their parents underwent complete exome sequencing of the peripheral blood. Both children had CLMP gene exons 3–5 homozygous deletion mutation, while the parents had a heterozygous mutation.Conclusion: This study identified a novel mutation of the CLMP gene in a Chinese family with CSBS. Identification of this mutation can help with genetic counseling and prenatal diagnosis of CSBS.
- 17 January 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9, 778859
Open AccessCongenital Short-Bowel Syndrome Is Associated With a Novel Deletion Mutation in the CLMP Gene: Mutations in CLMP Caused CSBS
Objective: To describe the clinical presentation and novel mutation in the coxsackie and adenovirus receptor-like membrane protein (CLMP) gene in a Chinese family with congenital short bowel syndrome (CSBS).Methods: We collected clinical data from a Chinese family with inherited CSBS, and performed whole exon sequencing of the children and their parents. The pathogenic sites of candidate genes were targeted, and the detected exon deletions were verified by quantitative PCR.Results: Two siblings in this family presented with bilious vomiting, and were diagnosed with CSBS on laparotomy. Two siblings and their parents underwent complete exome sequencing of the peripheral blood. Both children had CLMP gene exons 3–5 homozygous deletion mutation, while the parents had a heterozygous mutation.Conclusion: This study identified a novel mutation of the CLMP gene in a Chinese family with CSBS. Identification of this mutation can help with genetic counseling and prenatal diagnosis of CSBS.
- 13 August 2021
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 15 (13) , 1085-1095
Prognostic and Diagnostic Roles of Prolyl 4-Hydroxylase Subunit α Members in Breast Cancer
Aim: We aimed to evaluate the diagnostic and prognostic values of P4HAs in breast cancer (BC) patients. Materials & methods: Kaplan–Meier plotter was used to evaluate the prognostic values of P4HAs...
- 13 August 2021
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 15 (13) , 1085-1095
Prognostic and Diagnostic Roles of Prolyl 4-Hydroxylase Subunit α Members in Breast Cancer
Aim: We aimed to evaluate the diagnostic and prognostic values of P4HAs in breast cancer (BC) patients. Materials & methods: Kaplan–Meier plotter was used to evaluate the prognostic values of P4HAs...
- 1 May 2020
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 39 (5) , 909-917
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer
The aims of this study were to investigate the expression of prolyl 4-hydroxylase subunit alpha-1 (P4HA1) and its relationship with clinicopathological features in lung cancer (LC), breast cancer (BC), and head and neck cancer (HNSC) and to discuss the possibility of P4HA1 being a potential diagnostic and prognostic biomarker. Data on the RNA expression profile, protein expression profile, and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas databases. The relationship between P4HA1 mRNA expression and clinicopathological features was evaluated. Survival analysis was performed to assess overall survival (OS) and relapse-free survival (RFS). The multivariate Cox regression model was employed to analyze the independent prognostic factors. Finally, protein–protein interaction networks were constructed and enrichment analysis was performed to identify the latent P4HA1-related terms and pathways. This study showed that P4HA1 was upregulated in three types of tumor tissues (p < 0.05) and high P4HA1 was significantly relevant to the clinical features of patients with LC, BC, or HNSC. Survival analysis indicated that patients with high P4HA1 had unfavorable clinical outcomes. Multivariate analysis showed that the high P4HA1 expression was an independent prognostic factor for poor OS and RFS in LC and HNSC patients. Bioinformatic analysis was performed to predict P4HA1-interacted proteins and further evaluate possible signal pathways. In the current study, the rising P4HA1 was identified in LC, BC, and HNSC and significantly correlated with the clinicopathological features of patients. High P4HA1, suggesting poor clinical outcomes, could be used as an early diagnostic and prognostic biomarker for patients with aforementioned tumors.
- 1 May 2020
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 39 (5) , 909-917
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer
The aims of this study were to investigate the expression of prolyl 4-hydroxylase subunit alpha-1 (P4HA1) and its relationship with clinicopathological features in lung cancer (LC), breast cancer (BC), and head and neck cancer (HNSC) and to discuss the possibility of P4HA1 being a potential diagnostic and prognostic biomarker. Data on the RNA expression profile, protein expression profile, and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas databases. The relationship between P4HA1 mRNA expression and clinicopathological features was evaluated. Survival analysis was performed to assess overall survival (OS) and relapse-free survival (RFS). The multivariate Cox regression model was employed to analyze the independent prognostic factors. Finally, protein–protein interaction networks were constructed and enrichment analysis was performed to identify the latent P4HA1-related terms and pathways. This study showed that P4HA1 was upregulated in three types of tumor tissues (p < 0.05) and high P4HA1 was significantly relevant to the clinical features of patients with LC, BC, or HNSC. Survival analysis indicated that patients with high P4HA1 had unfavorable clinical outcomes. Multivariate analysis showed that the high P4HA1 expression was an independent prognostic factor for poor OS and RFS in LC and HNSC patients. Bioinformatic analysis was performed to predict P4HA1-interacted proteins and further evaluate possible signal pathways. In the current study, the rising P4HA1 was identified in LC, BC, and HNSC and significantly correlated with the clinicopathological features of patients. High P4HA1, suggesting poor clinical outcomes, could be used as an early diagnostic and prognostic biomarker for patients with aforementioned tumors.